Brillance Sp. z o.o
Brillance Sp. z o.o is recorded as a service provider in 8 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 8 of 8 trials · Latest update first
Ublituximab in Pediatric Participants with Relapsing forms of Multiple Sclerosis (RMS)
Sponsor Tg Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
Effectiveness of Trazodone on Emotional Blunting in Patients with Major Depressive: a Phase IV, Open-label, clinical study
Sponsor Angelini Pharma Italia Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. Enunciabile Anche Angelini Pharma Italia S.p.A. Angelini Pharma S.p.A. A.C.R.A.F. S.p.A. Acraf S.p.A. Angelini S.p.A. aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A.
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
A Phase 2, Multicenter, Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Ublituximab Administered at Various Injection Sites and Relative Bioavailability via Autoinjector Device versus Syringe in Patients with Multiple Sclerosis
Sponsor Tg Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis
Sponsor Tg Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
An Open-Label, Multicenter, Prospective, Interventional Study to Assess the Role of Pancreatic Enzyme Replacement Therapy (PERT) (Creon® 35,000) in Patients with Pancreatic Exocrine Insufficiency (PEI) after Pancreatic Surgery
Sponsor MEDA Pharma GmbH & Co. KG
- Start (EU)
- Latest update
- Estimated end
- Not reported
Pharmacokinetic/pharmacodynamic evaluation of ublituximab in patients with autoimmune diseases
Sponsor Tg Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
- Not reported
Evaluating safety, efficacy and pharmacokinetics of a modified regimen of ublituximab (ENHANCE)
Sponsor Tg Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
An open-label, multicenter, prospective, single-arm, exploratory study to assess role of pancreatic enzyme replacement therapy (PERT) (Creon® 25,000) in patients with Pancreatic Exocrine Insufficiency (PEI) after total gastrectomy.
Sponsor BGP Products Operations GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for Brillance Sp. z o.o?
The 2026-10-09 snapshot links Brillance Sp. z o.o to 8 distinct CTIS trials. Recorded services include Clinical monitoring, Investigator recruitment, Project management, Regulatory services, among 6 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Brillance Sp. z o.o?
The most frequently recorded therapeutic areas are Immunology, Neurology. Recorded phases include Phase 2, Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Brillance Sp. z o.o conducted?
The linked trials record locations in 10 countries, including Poland, Spain, Austria, Bulgaria, Germany. These are trial locations, not confirmed office locations or countries where Brillance Sp. z o.o delivered services.
What can this page tell me about Brillance Sp. z o.o's trial experience?
Browse 8 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Brillance Sp. z o.o. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Brillance Sp. z o.o.